Developer docs
API playgroundTry for free, no card

Search company profiles

Phylo

Full company profile

uuid028wjtz

Namestring
Phylo
Legal namestring
Phylo, Inc.
Websiteurl
phylo.bio
Company typeenum
Private
Founded yearint
2026
Descriptiontext

Phylo, Inc. is a Stanford AI Lab spin-out that builds Biomni Lab, a cloud-hosted Integrated Biology Environment (IBE) in which multi-agent AI agents orchestrate 300+ biomedical databases, software systems, and analytical tools to plan and execute end-to-end biomedical research workflows. The platform is anchored by a proprietary reinforcement-learning agent (Biomni-R0) tailored to biomedicine and a proprietary biomedical knowledge graph that captures every analysis, hypothesis, and decision trace from user sessions. Each session runs in a sandboxed environment with dedicated CPU, autoscaling GPU, and HPC access for specialized bio-AI models (AlphaFold, OpenFold 3, Boltz-2, ESMC-6B/ESMFold2, Evo 2, RNAPro, CodonFM).

The company serves biomedical research labs in academia and biotech, biopharmaceutical R&D organizations, healthcare systems, and AI-for-biology developers. Adoption signals include 7,000+ research labs and 4,300+ organizations using the open-source Biomni project, 8,400 preview users including 18 of the world's top 20 pharmaceutical companies, and named deployments at Ginkgo Bioworks and Mount Sinai. Scientific advisors include Nobel Laureate Carolyn Bertozzi, CRISPR pioneer Feng Zhang, and computational biologist Fabian Theis.

Phylo monetizes through a freemium self-serve product (Free tier, $100/month Pro with an .edu discount, $100/seat/month Team) plus custom-priced Enterprise contracts that include white-glove onboarding, SSO/RBAC, and customer-hosted VPC deployment. Distribution combines a self-serve PLG funnel, direct enterprise sales, a strategic GTM partnership with ZS, and embedded technology integrations with NVIDIA BioNeMo, Boltz, Biohub, and licensed data providers (Consensus, COSMIC, Addgene, GeneCards). The company is privately held, headquartered in South San Francisco, California, and closed a $13.5M seed round in February 2026 co-led by Andreessen Horowitz and Menlo Ventures' Anthology Fund.

Short descriptiontext

Phylo provides Biomni Lab, an AI-native Integrated Biology Environment in which multi-agent AI workflows orchestrate 300+ biomedical databases, models, and tools to plan and execute end-to-end biomedical research for academic labs, biotech, top-20 pharma, and healthcare systems.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomedical AI agents, drug discovery software, bioinformatics software, AI research platform, clinical trial emulation
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAH
Sample / Biorepository & Biobank Informatics (Chain-of-Custody)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Software Publishers513210
  • Computer Systems Design and Related Services5415
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
Product category
AI Biomedical Research Platform
Social media profiles2 records
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model5 records
1Free / Individual Tier
TypeFreemium
Description

Free self-serve tier with private workspace, full data ownership, concurrent task support, and HPC CPU/GPU access. Currently positioned as a free research preview but designed as a permanent freemium entry point.

phylo.bio
2Pro Subscription
TypeSubscription Recurring
Description

Pro plan at $100/month ($50/month with .edu email) for individual researchers, with 10x daily usage vs Free, more concurrent tasks, more compute, priority HPC access, and 7-day free trial. Recurring monthly billing with cancel anytime.

phylo.bio
3Team Subscription
TypeSubscription Recurring
Description

Team plan at $100/seat/month (discounted from $120) for startups and academic labs, with centralized admin workspace and billing, admin controls, and team collaboration features. Per-seat recurring subscription.

phylo.bio
4Enterprise Contracts
TypeManaged Services
Description

Enterprise tier with custom pricing for large organizations, including custom agent development, internal data and tool integrations, unlimited daily usage, expandable compute and storage, flexible deployment (multi-tenant, single-tenant, or customer-hosted VPC), SSO, RBAC, white-glove onboarding, and enterprise-grade encryption. Includes professional services for custom integrations.

phylo.bio
5Licensed Materials & Data Monetization (partnership/embedded fees)
TypeLicensing Royalties
Description

Phylo licenses proprietary third-party data and materials (e.g., Consensus for academic literature, COSMIC for cancer genomics, Addgene for plasmid discovery) and embeds them in Biomni Lab, granting end users limited sub-licensed access. Enterprise customers can pay for proprietary data and tool integrations.

seekingalpha.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Pricing details4 tiers
1Individual Free — full-featured free plan for exploring Biomni Lab
ModelFreemiumBilling cadencePay-as-you-go
Notes

$0/month. No credit card required. Private, secure workspace; user owns generated IP; supports concurrent tasks with scalable infra/compute; supports HPC CPU & GPU jobs.

phylo.bio
2Pro — paid plan for individual researchers
ModelSubscriptionBilling cadenceMonthly
Notes

$100/month standard, $50/month with .edu email. Includes 10x daily usage vs Free, more concurrent tasks, more compute and higher memory, priority access to HPC jobs, 7-day free trial, cancel anytime.

phylo.bio
3Team — for startups and academic labs
ModelPer seatBilling cadenceMonthly
Notes

$100/seat/month (limited time discount from $120). Includes everything in Pro plus centralized admin workspace and billing, admin controls, and team collaboration features.

phylo.bio
4Enterprise — custom for large organizations
ModelOtherBilling cadenceAnnual
Notes

Custom pricing. Includes integrations with internal data/tools/workflows, unlimited daily usage, expandable compute and storage, flexible deployment (multi-tenant, single-tenant, customer-hosted VPC), white-glove onboarding, SSO, RBAC, enterprise-grade encryption and compliance.

phylo.bio
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Biomni Lab
Description

Biomni Lab is the first Integrated Biology Environment (IBE), a unified AI-native workspace where biologists orchestrate AI agents across 300+ databases, software systems, and analytical tools to design experiments, analyze data, and accelerate biomedical research.

phylo.bio
+1 more record
Core offering1 text field

Phylo provides Biomni Lab, the first Integrated Biology Environment (IBE) — a unified cloud workspace where biologists collaborate with multi-agent AI to plan, execute, and review biomedical research end-to-end. The platform orchestrates 300+ biomedical databases, software systems, and analytical tools within sandboxed environments and is anchored by the Biomni-R0 reinforcement learning agent and a proprietary biomedical knowledge graph. It is offered alongside an open-source Biomni community edition and sold to enterprise biopharma, biotech, healthcare systems, and individual researchers via freemium, Pro, Team, and custom Enterprise tiers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Compresses weeks-long biomedical workflows down to hours (Ginkgo Bioworks case study: 10+ cell-painting and transcriptomic analyses)
+5 more records
Product overview1 text field

Phylo offers a single unified product platform, Biomni Lab, built on its Integrated Biology Environment (IBE) architecture, with an open-source community edition called Biomni available alongside it. Biomni Lab is the hosted, enterprise-grade core platform (SOC 2 Type 2 and ISO 27001 compliant) that orchestrates autonomous AI biology agents across add-on capabilities such as the UK Biobank Skill (500,000-person cohort analysis) and agent-managed sandboxes (isolated compute for executing analyses), plus integrations with NVIDIA BioNeMo, Boltz, GeneCards, and Biohub models (ESMC-6B, ESMFold2). The open-source Biomni release serves as the community counterpart to the hosted Biomni Lab, together comprising Phylo's Integrated Biology Environment portfolio for AI-driven biomedical research.

Product and service2 records
1Biomni Lab
CategoryAI biomedical research platform / Integrated Biology Environment
2Biomni (open source)
CategoryOpen-source biomedical AI agent
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierFlagship Infrastructure PartnerTypeTechnology or IntegrationAnnounced on2026-06-23
Description

Biomni Lab integrates resources from NVIDIA's BioNeMo open development platform as scientific skills and open models, starting with AlphaFold Database structures, synthetic protein scaffold datasets, and models including RNAPro, CodonFM, La-Proteina, GenMol, ReaSyn, and OpenFold 3. Users connect via NVIDIA NIM API keys.

Strategic tierCore Model PartnerTypeTechnology or IntegrationAnnounced on2026-06-16
Description

Biomni Lab integrates Boltz-2 (structure and affinity prediction) and BoltzGen (de novo binder design) via user-provided API keys in Settings → Integrations → Boltz. Enables folding, scoring, and design of protein, peptide, antibody, and nanobody binders, plus virtual screening and synthesizable small-molecule generation.

Strategic tierCore Model PartnerTypeTechnology or IntegrationAnnounced on2026-05-27
Description

Biohub's latest protein models (ESMC-6B and ESMFold2) are deployed on Biomni Lab's HPC cluster and accessible directly from chat without setup or GPU provisioning, enabling residue-level embeddings, zero-shot variant effect prediction, and structure prediction.

Strategic tierFlagship Enterprise Gtm PartnerTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-11
Description

ZS (15,000+ employee management consulting and technology firm) partnered with Phylo to bring agentic AI into enterprise R&D. Together they deploy Biomni Lab for bioinformatics pipelines, literature reasoning, molecule/protocol design, hypothesis generation, and bio foundation model fine-tuning, supported by ZS's research strategy, data integration, governance, and enterprise adoption expertise.

5Manuel Rivas (Stanford Biomedical Data Science)
Strategic tierResearch CollaboratorTypeStrategic or Co-development PartnerAnnounced on2026-05-06
Description

Co-developed the Genetic Target Hypothesis Biomni skill with Prof. Manuel Rivas at Stanford Biomedical Data Science, which transforms UK Biobank rare-variant burden statistics into ranked therapeutic target hypotheses in minutes.

phylo.bio
Strategic tierData Provider PartnerTypeTechnology or IntegrationAnnounced on2026-04-23
Description

Biomni Lab integrates GeneCards to ground biomedical agentic queries in a comprehensive biomedical knowledge base.

Strategic tierFlagship Case Study PartnerTypeStrategic or Co-development PartnerAnnounced on2026-02-03
Description

Joint case study validating Biomni Lab in a real production environment. Ginkgo's Datapoints team used Biomni Lab to accelerate over 10 complex cell-painting and transcriptomic analyses, compressing weeks-long workflows into hours and producing publication-quality results validated by Ginkgo scientists. Quoted by Ayla Ergun, Senior Director of Data Science at Ginkgo Bioworks.

Strategic tierData Provider PartnerTypeTechnology or IntegrationAnnounced on2026-02-03
Description

Consensus is integrated as a licensed data source for large-scale academic literature access inside Biomni Lab.

Strategic tierData Provider PartnerTypeTechnology or IntegrationAnnounced on2026-02-03
Description

COSMIC is integrated as a licensed data source for cancer genomics data inside Biomni Lab.

Strategic tierData Provider PartnerTypeTechnology or IntegrationAnnounced on2026-02-03
Description

Addgene is integrated as a licensed data source for plasmid discovery inside Biomni Lab.

Strategic tierClinical Research PartnerTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Phylo published a case study with Mount Sinai on scaling agentic clinical trial emulation using real-world EHR data, demonstrating Biomni Lab's use for clinical and translational research. Ben Glicksberg (Phylo Founding Advisor) is affiliated with the Icahn School of Medicine at Mount Sinai.

Strategic tierFoundational / Spin-Out PartnerTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

Phylo spun out of the Biomni open-source research project at Stanford AI Lab, which the founding team started in June 2024. The company maintains the Biomni open-source project and continues collaborations with academic groups at Stanford, including a co-developed Genetic Target Hypothesis skill with Prof. Manuel Rivas at Stanford Biomedical Data Science.

13Carolyn Bertozzi (Scientific Advisor)
Strategic tierFlagship Scientific AdvisorTypeOthers
Description

Nobel Laureate Carolyn Bertozzi, leading figure in biochemistry, joined Phylo as a scientific advisor to guide scientific direction.

phylo.bio
14Feng Zhang (Scientific Advisor)
Strategic tierFlagship Scientific AdvisorTypeOthers
Description

CRISPR pioneer Feng Zhang, leading figure in genomics, joined Phylo as a scientific advisor.

phylo.bio
15Fabian Theis (Scientific Advisor)
Strategic tierScientific AdvisorTypeOthers
Description

Fabian Theis, leading figure in computational biology (TUM, Helmholtz Munich), joined Phylo as a scientific advisor and provided a public endorsement of Biomni's vision.

phylo.bio
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Profluent Bio develops AI foundation models for protein design and engineering. It is comparable to Phylo because both push bio-AI foundation models into biotech R&D, though Profluent is a model-first company while Phylo is a platform/orchestration layer that integrates Profluent-adjacent capabilities.

TypeBroad incumbent
Description

Dotmatics (part of Siemens-owned Dotmatics/GraphPad) is a life sciences R&D platform spanning ELN, data management and analytics for pharma/biotech. It is comparable to Phylo as a horizontal research platform for biologists, but lacks the agentic multi-agent architecture that defines Biomni Lab.

TypeDirect peer
Description

FutureHouse builds AI 'crow' agents (e.g., Robin, Falcon) that automate scientific literature review and reasoning tasks. It is comparable to Phylo's Biomni Lab because both deploy multi-agent systems to execute biomedical research workflows end-to-end, though FutureHouse is more literature- and reasoning-focused while Phylo spans wet-lab execution.

TypeBroad incumbent
Description

Schrödinger provides computational chemistry and materials simulation software widely used in pharma R&D. It is comparable to Phylo as an established incumbent selling AI/ML tooling into biopharma research, but operates at the molecular simulation layer rather than orchestrating the broader research workflow.

TypeBroad incumbent
Description

Recursion is a publicly listed AI-driven drug discovery company combining high-throughput wet-lab experimentation with ML. It is comparable to Phylo as a broader incumbent in AI-for-biology with established pharma partnerships, though it is far larger and more vertically integrated into its own pipeline.

TypeEmerging player
Description

Cradle provides AI-powered protein design tooling for biotech R&D teams. It is comparable to Phylo because it sits inside the same AI-for-biology stack (and competes with Phylo's Boltz/ESMC integrations), but focuses narrowly on protein engineering rather than spanning the full research workflow.

TypeDirect peer
Description

Benchling is the leading cloud R&D platform for biologists, offering notebooks, registry, inventory and assay workflows plus an emerging AI/agent layer. It is the closest direct peer to Phylo's Biomni Lab because both target biomedical research teams with a unified software environment, but Benchling is more focused on lab data management while Phylo leans agentic and tool-orchestration.

TypeEmerging player
Description

EvolutionaryScale develops large-scale biological foundation models (e.g., Evo) for genomics and protein design. It is comparable to Phylo as a bio-AI ecosystem player, but operates at the model layer (which Phylo integrates via Boltz, BioNeMo and OpenFold-style models) rather than as a research workspace.

TypeDirect peer
Description

Lila Sciences is building an 'AI science factory' that combines autonomous labs with foundation models for scientific discovery. It is directly comparable to Phylo because both pursue agentic AI for biology at scale with significant capital backing and a similar narrative of compressing research timelines.

TypeDirect peer
Description

Insitro combines ML/AI with high-throughput biology for drug discovery. It is comparable to Phylo because both serve biopharma R&D with AI-augmented biology workflows, though Insitro is more vertically integrated into proprietary drug programs while Phylo sells a horizontal research platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration12 records

Each record includes

Title, Type, Description, Source

AI capability12 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phylo

AI Biomedical Research Platformphylo.bio

Phylo provides Biomni Lab, an AI-native Integrated Biology Environment in which multi-agent AI workflows orchestrate 300+ biomedical databases, models, and tools to plan and execute end-to-end biomedical research for academic labs, biotech, top-20 pharma, and healthcare systems.

What Phylo does

Phylo, Inc. is a Stanford AI Lab spin-out that builds Biomni Lab, a cloud-hosted Integrated Biology Environment (IBE) in which multi-agent AI agents orchestrate 300+ biomedical databases, software systems, and analytical tools to plan and execute end-to-end biomedical research workflows. The platform is anchored by a proprietary reinforcement-learning agent (Biomni-R0) tailored to biomedicine and a proprietary biomedical knowledge graph that captures every analysis, hypothesis, and decision trace from user sessions. Each session runs in a sandboxed environment with dedicated CPU, autoscaling GPU, and HPC access for specialized bio-AI models (AlphaFold, OpenFold 3, Boltz-2, ESMC-6B/ESMFold2, Evo 2, RNAPro, CodonFM).

The company serves biomedical research labs in academia and biotech, biopharmaceutical R&D organizations, healthcare systems, and AI-for-biology developers. Adoption signals include 7,000+ research labs and 4,300+ organizations using the open-source Biomni project, 8,400 preview users including 18 of the world's top 20 pharmaceutical companies, and named deployments at Ginkgo Bioworks and Mount Sinai. Scientific advisors include Nobel Laureate Carolyn Bertozzi, CRISPR pioneer Feng Zhang, and computational biologist Fabian Theis.

Phylo monetizes through a freemium self-serve product (Free tier, $100/month Pro with an .edu discount, $100/seat/month Team) plus custom-priced Enterprise contracts that include white-glove onboarding, SSO/RBAC, and customer-hosted VPC deployment. Distribution combines a self-serve PLG funnel, direct enterprise sales, a strategic GTM partnership with ZS, and embedded technology integrations with NVIDIA BioNeMo, Boltz, Biohub, and licensed data providers (Consensus, COSMIC, Addgene, GeneCards). The company is privately held, headquartered in South San Francisco, California, and closed a $13.5M seed round in February 2026 co-led by Andreessen Horowitz and Menlo Ventures' Anthology Fund.

Phylo firmographics

Firmographics
Name
Phylo
Legal name
Phylo, Inc.
Website
https://phylo.bio
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
11–50 employees
Short description
Phylo provides Biomni Lab, an AI-native Integrated Biology Environment in which multi-agent AI workflows orchestrate 300+ biomedical databases, models, and tools to plan and execute end-to-end biomedical research for academic labs, biotech, top-20 pharma, and healthcare systems.
Ownership category
akta.pro rank

Phylo industry classification

Industry
Product category
AI Biomedical Research Platform
NAICS
Software Publishers (513210), Computer Systems Design and Related Services (5415)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAH
Sample / Biorepository & Biobank Informatics (Chain-of-Custody)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Biomedical AI agents
  • Drug discovery software
  • Bioinformatics software
  • AI research platform
  • Clinical trial emulation

Where Phylo is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Phylo business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Free / Individual Tier: Free self-serve tier with private workspace, full data ownership, concurrent task support, and HPC CPU/GPU access. Currently positioned as a free research preview but designed as a permanent freemium entry point.
  2. Pro Subscription: Pro plan at $100/month ($50/month with .edu email) for individual researchers, with 10x daily usage vs Free, more concurrent tasks, more compute, priority HPC access, and 7-day free trial. Recurring monthly billing with cancel anytime.
  3. Team Subscription: Team plan at $100/seat/month (discounted from $120) for startups and academic labs, with centralized admin workspace and billing, admin controls, and team collaboration features. Per-seat recurring subscription.
  4. Enterprise Contracts: Enterprise tier with custom pricing for large organizations, including custom agent development, internal data and tool integrations, unlimited daily usage, expandable compute and storage, flexible deployment (multi-tenant, single-tenant, or customer-hosted VPC), SSO, RBAC, white-glove onboarding, and enterprise-grade encryption. Includes professional services for custom integrations.
  5. Licensed Materials & Data Monetization (partnership/embedded fees): Phylo licenses proprietary third-party data and materials (e.g., Consensus for academic literature, COSMIC for cancer genomics, Addgene for plasmid discovery) and embeds them in Biomni Lab, granting end users limited sub-licensed access. Enterprise customers can pay for proprietary data and tool integrations.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goIndividual Free — full-featured free plan for exploring Biomni Lab
SubscriptionMonthlyPro — paid plan for individual researchers
Per seatMonthlyTeam — for startups and academic labs
OtherAnnualEnterprise — custom for large organizations

Go-to-market motion5 records

Distribution channels5 records

Marketing channels10 records

Phylo product offering

Product offering

Core offering

Phylo provides Biomni Lab, the first Integrated Biology Environment (IBE) — a unified cloud workspace where biologists collaborate with multi-agent AI to plan, execute, and review biomedical research end-to-end. The platform orchestrates 300+ biomedical databases, software systems, and analytical tools within sandboxed environments and is anchored by the Biomni-R0 reinforcement learning agent and a proprietary biomedical knowledge graph. It is offered alongside an open-source Biomni community edition and sold to enterprise biopharma, biotech, healthcare systems, and individual researchers via freemium, Pro, Team, and custom Enterprise tiers.

Product overview

Phylo offers a single unified product platform, Biomni Lab, built on its Integrated Biology Environment (IBE) architecture, with an open-source community edition called Biomni available alongside it. Biomni Lab is the hosted, enterprise-grade core platform (SOC 2 Type 2 and ISO 27001 compliant) that orchestrates autonomous AI biology agents across add-on capabilities such as the UK Biobank Skill (500,000-person cohort analysis) and agent-managed sandboxes (isolated compute for executing analyses), plus integrations with NVIDIA BioNeMo, Boltz, GeneCards, and Biohub models (ESMC-6B, ESMFold2). The open-source Biomni release serves as the community counterpart to the hosted Biomni Lab, together comprising Phylo's Integrated Biology Environment portfolio for AI-driven biomedical research.

Differentiator

Problem solved

Functional benefit

Brands

  • Biomni Lab: Biomni Lab is the first Integrated Biology Environment (IBE), a unified AI-native workspace where biologists orchestrate AI agents across 300+ databases, software systems, and analytical tools to design experiments, analyze data, and accelerate biomedical research.
  • Biomni (open-source project)

Products and services

  • Biomni Lab
  • Biomni (open source)

Quantifiable outcome

  • Compresses weeks-long biomedical workflows down to hours (Ginkgo Bioworks case study: 10+ cell-painting and transcriptomic analyses)
  • +5 more outcomes

Companies that use Phylo

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Phylo technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration12 records

AI capability12 records

Feature8 records

Phylo partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered flagship infrastructure partner, core model partner, flagship enterprise gtm partner, research collaborator, data provider partner, flagship case study partner, clinical research partner, foundational / spin-out partner, flagship scientific advisor and scientific advisor.

  • NVIDIA (BioNeMo)flagship infrastructure partnerTechnology or Integration · 23 June 2026Biomni Lab integrates resources from NVIDIA's BioNeMo open development platform as scientific skills and open models, starting with AlphaFold Database structures, synthetic protein scaffold datasets, and models including RNAPro, CodonFM, La-Proteina, GenMol, ReaSyn, and OpenFold 3. Users connect via NVIDIA NIM API keys.
  • Boltzcore model partnerTechnology or Integration · 16 June 2026Biomni Lab integrates Boltz-2 (structure and affinity prediction) and BoltzGen (de novo binder design) via user-provided API keys in Settings → Integrations → Boltz. Enables folding, scoring, and design of protein, peptide, antibody, and nanobody binders, plus virtual screening and synthesizable small-molecule generation.
  • Biohub (Chan Zuckerberg Biohub)core model partnerTechnology or Integration · 27 May 2026Biohub's latest protein models (ESMC-6B and ESMFold2) are deployed on Biomni Lab's HPC cluster and accessible directly from chat without setup or GPU provisioning, enabling residue-level embeddings, zero-shot variant effect prediction, and structure prediction.
  • ZSflagship enterprise gtm partnerImplementation/ SI/ Consulting Partner · 11 May 2026ZS (15,000+ employee management consulting and technology firm) partnered with Phylo to bring agentic AI into enterprise R&D. Together they deploy Biomni Lab for bioinformatics pipelines, literature reasoning, molecule/protocol design, hypothesis generation, and bio foundation model fine-tuning, supported by ZS's research strategy, data integration, governance, and enterprise adoption expertise.
  • Manuel Rivas (Stanford Biomedical Data Science)research collaboratorStrategic or Co-development Partner · 6 May 2026Co-developed the Genetic Target Hypothesis Biomni skill with Prof. Manuel Rivas at Stanford Biomedical Data Science, which transforms UK Biobank rare-variant burden statistics into ranked therapeutic target hypotheses in minutes.
  • GeneCardsdata provider partnerTechnology or Integration · 23 April 2026Biomni Lab integrates GeneCards to ground biomedical agentic queries in a comprehensive biomedical knowledge base.
  • Ginkgo Bioworksflagship case study partnerStrategic or Co-development Partner · 3 February 2026Joint case study validating Biomni Lab in a real production environment. Ginkgo's Datapoints team used Biomni Lab to accelerate over 10 complex cell-painting and transcriptomic analyses, compressing weeks-long workflows into hours and producing publication-quality results validated by Ginkgo scientists. Quoted by Ayla Ergun, Senior Director of Data Science at Ginkgo Bioworks.
  • Consensusdata provider partnerTechnology or Integration · 3 February 2026Consensus is integrated as a licensed data source for large-scale academic literature access inside Biomni Lab.
  • COSMICdata provider partnerTechnology or Integration · 3 February 2026COSMIC is integrated as a licensed data source for cancer genomics data inside Biomni Lab.
  • Addgenedata provider partnerTechnology or Integration · 3 February 2026Addgene is integrated as a licensed data source for plasmid discovery inside Biomni Lab.
  • Mount Sinaiclinical research partnerStrategic or Co-development Partner · 1 January 2026Phylo published a case study with Mount Sinai on scaling agentic clinical trial emulation using real-world EHR data, demonstrating Biomni Lab's use for clinical and translational research. Ben Glicksberg (Phylo Founding Advisor) is affiliated with the Icahn School of Medicine at Mount Sinai.
  • Stanford University (Stanford AI Lab)foundational / spin-out partnerStrategic or Co-development Partner · 1 June 2024Phylo spun out of the Biomni open-source research project at Stanford AI Lab, which the founding team started in June 2024. The company maintains the Biomni open-source project and continues collaborations with academic groups at Stanford, including a co-developed Genetic Target Hypothesis skill with Prof. Manuel Rivas at Stanford Biomedical Data Science.
  • Carolyn Bertozzi (Scientific Advisor)flagship scientific advisorOthersNobel Laureate Carolyn Bertozzi, leading figure in biochemistry, joined Phylo as a scientific advisor to guide scientific direction.
  • Feng Zhang (Scientific Advisor)flagship scientific advisorOthersCRISPR pioneer Feng Zhang, leading figure in genomics, joined Phylo as a scientific advisor.
  • Fabian Theis (Scientific Advisor)scientific advisorOthersFabian Theis, leading figure in computational biology (TUM, Helmholtz Munich), joined Phylo as a scientific advisor and provided a public endorsement of Biomni's vision.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Phylo competitors and assessment

Company assessment

Emerging players

  • Profluent Bio: Profluent Bio develops AI foundation models for protein design and engineering. It is comparable to Phylo because both push bio-AI foundation models into biotech R&D, though Profluent is a model-first company while Phylo is a platform/orchestration layer that integrates Profluent-adjacent capabilities.
  • Cradle: Cradle provides AI-powered protein design tooling for biotech R&D teams. It is comparable to Phylo because it sits inside the same AI-for-biology stack (and competes with Phylo's Boltz/ESMC integrations), but focuses narrowly on protein engineering rather than spanning the full research workflow.
  • EvolutionaryScale: EvolutionaryScale develops large-scale biological foundation models (e.g., Evo) for genomics and protein design. It is comparable to Phylo as a bio-AI ecosystem player, but operates at the model layer (which Phylo integrates via Boltz, BioNeMo and OpenFold-style models) rather than as a research workspace.

Broad incumbents

  • Dotmatics: Dotmatics (part of Siemens-owned Dotmatics/GraphPad) is a life sciences R&D platform spanning ELN, data management and analytics for pharma/biotech. It is comparable to Phylo as a horizontal research platform for biologists, but lacks the agentic multi-agent architecture that defines Biomni Lab.
  • Schrödinger: Schrödinger provides computational chemistry and materials simulation software widely used in pharma R&D. It is comparable to Phylo as an established incumbent selling AI/ML tooling into biopharma research, but operates at the molecular simulation layer rather than orchestrating the broader research workflow.
  • Recursion: Recursion is a publicly listed AI-driven drug discovery company combining high-throughput wet-lab experimentation with ML. It is comparable to Phylo as a broader incumbent in AI-for-biology with established pharma partnerships, though it is far larger and more vertically integrated into its own pipeline.

Direct peers

  • FutureHouse: FutureHouse builds AI 'crow' agents (e.g., Robin, Falcon) that automate scientific literature review and reasoning tasks. It is comparable to Phylo's Biomni Lab because both deploy multi-agent systems to execute biomedical research workflows end-to-end, though FutureHouse is more literature- and reasoning-focused while Phylo spans wet-lab execution.
  • Benchling: Benchling is the leading cloud R&D platform for biologists, offering notebooks, registry, inventory and assay workflows plus an emerging AI/agent layer. It is the closest direct peer to Phylo's Biomni Lab because both target biomedical research teams with a unified software environment, but Benchling is more focused on lab data management while Phylo leans agentic and tool-orchestration.
  • Lila Sciences: Lila Sciences is building an 'AI science factory' that combines autonomous labs with foundation models for scientific discovery. It is directly comparable to Phylo because both pursue agentic AI for biology at scale with significant capital backing and a similar narrative of compressing research timelines.
  • Insitro: Insitro combines ML/AI with high-throughput biology for drug discovery. It is comparable to Phylo because both serve biopharma R&D with AI-augmented biology workflows, though Insitro is more vertically integrated into proprietary drug programs while Phylo sells a horizontal research platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Phylo social profiles

Digital presence

Phylo compliance and trust

Trust signal

Compliance2 records

Phylo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phylo leadership team

Management profile

Number of profiles

Profiles10 records

Phylo funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phylo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phylo

What does Phylo do?

Phylo provides Biomni Lab, the first Integrated Biology Environment (IBE) — a unified cloud workspace where biologists collaborate with multi-agent AI to plan, execute, and review biomedical research end-to-end. The platform orchestrates 300+ biomedical databases, software systems, and analytical tools within sandboxed environments and is anchored by the Biomni-R0 reinforcement learning agent and a proprietary biomedical knowledge graph. It is offered alongside an open-source Biomni community edition and sold to enterprise biopharma, biotech, healthcare systems, and individual researchers via freemium, Pro, Team, and custom Enterprise tiers.

Is Phylo a public or private company?

Phylo is a private company. It is classified as venture growth investor backed and is currently operating.

When was Phylo founded?

Phylo was founded in 2026. It employs 11 to 50 people.

Where is Phylo based?

Phylo is headquartered in South San Francisco, United States, in the North America region.

How does Phylo make money?

Five revenue lines are on record. Free / Individual Tier is the primary driver. The others are pro Subscription, team Subscription, enterprise Contracts and licensed Materials & Data Monetization (partnership/embedded fees).

Who are Phylo's main competitors?

Emerging players on record are Profluent Bio, Cradle and EvolutionaryScale. Broad incumbents are Dotmatics, Schrödinger and Recursion. Direct peers are FutureHouse, Benchling, Lila Sciences and Insitro.

Does Phylo have an API?

Yes. Phylo's Biomni Lab platform exposes API-based integrations for third-party AI models and data sources. Users configure API keys in Settings → Integrations to connect providers such as NVIDIA BioNeMo (NIM) and Boltz. The Terms of Service reference an applicable application programming interface ('API') governing programmatic access to Biomni Lab. No public REST/GraphQL endpoints, rate limits, versioning, or developer portal details are publicly documented.

What industry is Phylo in?

Phylo's product category is AI Biomedical Research Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Unite.AIPhylo’s Target Atlas Puts AI Agents on Drug Target PrioritizationPhylo launched Target Atlas on September 29, 2026, an AI agent-based target-prioritization tool with a free public edition and a Parkinson's edition developed with The Michael J. Fox Foundation. The system aims to cut evidence-gathering from months to days, and Phylo plans to expand the public edition across major diseases.PR NewswirePhylo Launches Target Atlas to Speed Up Target PrioritizationPhylo launched Target Atlas, an AI-driven target-prioritization app built on Biomni Lab, with a free Parkinson's edition developed with The Michael J. Fox Foundation. The app can cut evidence-gathering from months to days, and Phylo plans to expand across diseases.Simply Wall StWhat Chugai Pharmaceutical (TSE:4519)'s Agentic AI Partnership With Phylo Means For ShareholdersChugai Pharmaceutical began rolling out an agentic AI platform across its drug discovery workflow in early 2026 and partnered with Phylo to apply the technology to single-cell data, human genetics and disease biology. The collaboration embeds the Biomni Lab AI platform into Chugai's discovery workflow, alongside filings to expand Tecentriq and Enspryng indications. Analysts project revenue of ¥1,741.7 billion and earnings of ¥712.1 billion by 2029, implying 9.1% yearly revenue growth.Pharmaceutical TechnologyPhylo, Chugai collaborate to deploy AI platform in drug discoveryPhylo has entered a collaboration with Japan-based Chugai Pharmaceutical to implement Biomni Lab, an agentic AI platform for biomedical research, within the latter's drug discovery operations. The platform will consolidate AI-driven capabilities and diverse biomedical resources into a single digital workspace, enabling Chugai researchers to interact with proprietary data and support decision-making across areas including single-cell analysis, disease biology, human genetics, and target evaluation. Phylo's CEO stated the vision is to help biopharma become AI-native, with Chugai selected as an ideal setting to demonstrate how agentic AI can accelerate breakthrough discovery.AInvestThe Wrong Company, the Right Question About AI Drug DiscoveryA July 2026 AI drug discovery partnership was mistakenly attributed to Chugai but correctly involves Phylo and Ono Pharmaceutical, the Osaka-based maker of the cancer immunotherapy Opdivo. Phylo, a Stanford-founded startup that launched commercially in February 2026 with a $13.5 million seed round, offers Biomni—an AI agent integrating 300+ scientific tools to accelerate researcher productivity rather than replace scientists, contrasting with molecule-design platforms like Insilico Medicine. Ono Pharmaceutical's adoption validates Phylo's approach, with Ginkgo Bioworks confirming accelerated analyses, though Phylo's success remains contingent on securing additional pharma partnerships beyond this first commercial deal.AijournPhylo and Chugai partner to advance AI agents in drug discoveryPhylo, Inc. announced a collaboration with Chugai Pharmaceutical Co., Ltd. to deploy Biomni Lab, Phylo's agentic AI platform for biomedical research, across Chugai's drug discovery workflows. The platform will integrate AI capabilities and hundreds of biomedical resources into Chugai's secure research environment to support single-cell analysis, human genetics, disease biology, and target evaluation. This partnership marks Chugai's entry as a founding customer and is intended to help Chugai shorten discovery timelines and improve the probability of success in its drug programs.YahooPhylo and Chugai partner to advance AI agents in drug discoveryPhylo, Inc. announced a collaboration with Chugai Pharmaceutical Co., Ltd. to deploy Biomni Lab, Phylo's agentic AI platform for biomedical research, across Chugai's drug discovery workflows. The platform integrates AI capabilities and hundreds of biomedical resources into a single workspace, enabling Chugai scientists to convert proprietary research data into stronger hypotheses and more informed decisions. The partnership aims to support Chugai across multiple areas including single-cell analysis, human genetics, disease biology, and target evaluation, with the goal of shortening discovery timelines and improving program success rates.PR NewswirePhylo and Chugai partner to advance AI agents in drug discoveryPhylo, Inc. announced a partnership with Chugai Pharmaceutical Co., Ltd. to deploy its AI platform, Biomni Lab, across Chugai's drug discovery workflows. The collaboration aims to improve efficiency and success rates in various drug discovery areas by integrating AI with proprietary data.MorningstarPhylo and Chugai partner to advance AI agents in drug discoveryPhylo and Chugai announced a partnership to deploy Phylo's Biomni Lab AI platform across Chugai's drug discovery workflows. The platform connects proprietary research data to help scientists generate hypotheses and shorten discovery timelines. Chugai joins Phylo's founding customers, a select group of research organizations.PrtimesOno Pharmaceutical begins collaboration with Phylo to utilize agent-based AI platform in drug discovery research.Ono Pharmaceutical announced a collaboration with Phylo to use Phylo's Biomni Lab agent-based AI platform for drug discovery research. The partnership aims to accelerate the process from hypothesis building to drug candidate creation by combining Ono's research knowledge with Phylo's AI infrastructure. Ono's research division head said they will verify how agent-based AI can deliver new drugs more quickly.